Scancell founder says the company is ready to commercialise novel medicines to counteract cancer. Watch the video here.
Has the 2 week study started:
From C6 completion RNS:
The excellent safety profile of AVA6000 should allow more frequent and/or higher dosing compared with the standard doxorubicin regimen which could in turn improve the outcome for patients.
“Therefore, in parallel with the completion of cohort 7, the Company intends to begin a short study to explore more frequent dosing (fortnightly) of AVA6000 as a first line treatment in patients with soft tissue sarcoma. The study is expected to begin in Q4 2023 subject to receipt of approval of a protocol amendment from the US Food & Drug Administration (FDA).”
Now look at this:
Do protocol amendments require FDA approval?
FDA does not issue “permissions” or “approvals” for protocol amendments, your changes are effective immediately upon the receipt of your amendment by the FDA.
The IRB may request documentation of FDA review of amendments and may hold approval until documentation is received from the FDA.
https://ssri.psu.edu/clinicalresearchguidebook/reporting-new-information-fda-and-sponsor#:~:text=FDA%20does%20not%20issue%20%E2%80%9Cpermissions,is%20received%20from%20the%20FDA.
My take, fortnightly dosing is taken place now along side C7 if IRB have not requested documentation.
Avacta don’t need to RNS fortnightly dosing they did that in last RNS.
If the sixth dose cohort at 310 mg/m2, which is equivalent to 2.7 times the standard dose of doxorubicin has shown a significant reduction in tumour volume.
Then what will 385 mg/m2, which is equivalent to approximately 3.5 times the standard dose of doxorubicin be doing to these tumours….
Roll on the next RNS…
GLA
Imagine being told you have months to live and offered the chance to take part in a new trial that will put more chemo and less side effects into your body to make your last few months more tolerable.
Image walking into one of the best cancer clinics in the world in MSK on your first day in clinic and meeting other patients in the same position as you.
Imagine just a few months later you have no side effects and your doctor tells you the cancer has stopped growing.
Imagine your doctor then telling you your tumour is shrinking.
Imagine starting a new cohort with even more chemo put into your body and still no side effects.
Imagine seeing the other patients you started your chemo with in April and all of them are still alive.
Imagine your family and friends looking forward to Christmas with you,when you thought you would have passed by now.
Imagine what the reaction will be when your trial data goes public.
Coming soon well done Avacta
Never mind….
Anyone know when it’s Telegram day
Just in case my alarm doesn’t go off
Happy Sujood day tomorrow everyone….
😜
Roll on Data Avacta could end up with a very valuable platform.
Platform technology provides a better, more cost-effective way forward.
The new paradigm in drug development: Why platform technology is the solution patients and payers need.
https://medcitynews.com/2022/05/the-new-paradigm-in-drug-development-why-platform-technology-is-the-solution-patients-and-payers-need/
I rritable
G rotesque
N oise
O dd
R epetitive
E xcruciating
12 trading days left in November
For full impact on media Avacta shouldn’t release data on these dates:
Inflation figures 15th Nov
Autumn Budget 22nd Nov
Black Friday 24th Nov
So if not this week
Doesn’t look likely next week
So my guess last week in November W/C 27th Nov
Come Avacta Welease Wodger
GLA…
Dr Eliot Forster, Chairman of Avacta Group plc added:
"Targeting of cancer therapies to tumour tissue has been a long sought after goal for many oncology drug companies, clinicians and patients. There are many potent anti-cancer drugs, the effectiveness of which is limited by the systemic toxicities and lack of tolerability for patients.
Well the many will start knocking soon….
“Avacta couldn’t spell it out any clearer, but still the trolls keep trying to spin negativity”
Why put “Revolutionising
the treatability of solid tumours” on a massive screen outside your office
If it didn’t work ?
Why does CEO state in a RNS
“One patient with soft tissue sarcoma has shown a significant reduction in tumour volume in response to the drug”
If it didn’t work ?
Why does CEO states in a RNS
"I believe that we are on the verge of a paradigm shift in how chemotherapy is delivered to cancer patients.”
If it didn’t work?
Why does the CEO answer when asked about future funding :
“don’t you worry about that”
If it didn’t work ?
Why does the Consultant Chief Medical Officer state in a RNS
"We have potential to exploit AVA6000 to treat other cancers such as breast and ovarian and a wealth of opportunities to build our pipeline and partnerships.
If it didn’t work ?
Why does the Chairman of Avacta Group states in a RNS
"The clinical data emerging for our lead pre|CISIONTM drug, AVA6000, is ground-breaking. We are seeing a dramatic reduction in the usual toxicities associated with anthracycline chemotherapy and we have clear indications that doxorubicin is being released in active form in the tumour microenvironment.”
If it didn’t work ?
Why did Shaun Chilton join the board as Non-Executive Director
If it didn’t work ?
Why did Dr William Tap choose to work with a tiny Aim Biotech in Avacta and not accept larger rewards from BP
If it didn’t work ?
Why have the MHRA & FDA approved 7 cohorts with potential fatal doses of Dox
If it didn’t work ?
Why have Avacta concluded that a phase 1B is no longer required and will move straight to phase 2 and is on record as saying it works…
If it didn’t work ?
Avacta couldn’t spell it out any clearer, but still the trolls keep trying to spin negativity.
Hold on to your shares and wait for PK data for your rewards ….. GLA
This is why Avacta’s Pre/Cision platforms PK data will be on every BP board room table in the very near future.
AS and the Avacta board have played a blinder with timing of AVA6000.
According to Precedence Research, the global oncology market size worth at US$ 203.42 billion in 2022 and is predicted to reach over US$ 470.61 billion by 2032.
GLOBOCAN, has stated that approximately 19.3 million new cancer cases and about 10 million deaths related to cancer were recorded in 2020, across the globe. The IARC has estimated that the new cancer cases are expected to rise by 47% all over the globe from 2020 to 2040.
North America accounted for around 46% of the market share in 2022 and dominated the global oncology market.
https://www.precedenceresearch.com/oncology-market
Eliot Forster non executive chairman of Avacta became Protalix Bio Chairman mid September 2023.
Three weeks later Israel are at war.Just hope he stays safe in his new role:
Top man.
https://www.nasdaq.com/articles/protalix-biotherapeutics-appoints-eliot-richard-forster-to-succeed-zeev-bronfeld-as
https://protalixbiotherapeutics.gcs-web.com/node/13746/pdf
https://protalix.com/
Could a certain BP who may be running their eyes over Avacta and the Pre/Cision platform and all of Avacta’s other IP,be ready to trump Eli Lilly in the Point Bio deal.
Do they want all Pre/Cision licences under their control.
Pop corn ready it’s going to be a good Christmas ….
GLA…
Thanks Gmcc
This link better
Biotechnology Value Fund sees "negligible downside and the potential for significant upside for the issuer’s shareholders to await the results of the SPLASH Study prior to consummating the Acquisition," the investor said in the filing. "Accordingly, in the absence of the SPLASH Study results, the Reporting Persons do not intend to tender their Shares in support of the Acquisition in the initial tender period expiring November 9, 2023."
Plus they have pre/Cision licence also waiting on Q4 data
This is very interesting pod cast 18 mins in
Break through therapy harder to achieve than fast track.
FDA give a lot of guidance Avacta must be close to approval once they have PK data ready.
GLA…..
https://m.youtube.com/watch?v=U0kmxYRQQS0&feature=youtu.be
Well worth a watch
https://m.youtube.com/watch?v=ae2xENSTp4Y&pp=ygUOZHIgd2lsbGlhbSB0YXA%3D
GLA…
🦒to keep this thread going
This puts Eggy argument to bed:
18 mins in:
https://youtu.be/PWrjyiR-r6o?si=YEIBi-o-HXDkgg9L
Courtesy of @blueberrymgmnt from X (twitter)
Https://clinicaltrials.gov/study/NCT04969835?tab=history&a=1
SP still under £1.50 just buy now